Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study.

Publication date: Jul 07, 2026

PCSK9 inhibitors reduce major cardiovascular events in randomized trials of atherosclerotic cardiovascular disease (ASCVD), but real-world neuropsychiatric safety remains uncertain. In a propensity score-matched retrospective cohort study using the TriNetX U. S. Federated Research Network, adults with established ASCVD initiating alirocumab or evolocumab between 2017 and 2024 were matched 1:1 to statin-monotherapy initiators. The 12-month primary analysis assessed major adverse cardiovascular events (MACE: myocardial infarction, heart failure [HF], ischaemic stroke, all-cause death), neurodegenerative disease (dementia, Parkinson’s disease) and psychiatric disorders (psychosis, bipolar disorder, depression, anxiety), with Bonferroni correction and negative control. Secondary analyses examined individual agents, ASCVD subtypes, statin use, an intensified lipid-lowering comparator and extended follow-up. Among 60 885 matched pairs (mean age 70 years; 61% male), PCSK9 inhibitor therapy was associated with lower 12-month risks of MACE (HR 0. 84, 95% CI 0. 80-0. 88), myocardial infarction (HR 0. 82, 0. 79-0. 86), HF (HR 0. 87, 0. 83-0. 92) and all-cause mortality (HR 0. 40, 0. 37-0. 43); ischaemic stroke did not differ. After Bonferroni correction, no neurodegenerative association remained significant. PCSK9 inhibitor use was associated with higher risks of any psychiatric diagnosis (HR 1. 33, 1. 25-1. 42), depression (HR 1. 44, 1. 28-1. 61) and anxiety (HR 1. 39, 1. 28-1. 50), persisting in secondary analyses; negative control outcomes did not differ. PCSK9 inhibitor use was associated with favourable cardiovascular outcomes and no clear neurodegenerative harm, but higher rates of depression and anxiety. Given the observational design and potential residual confounding, statin-intolerance-related treatment selection and surveillance bias, these findings should be interpreted as hypothesis-generating and warrant further prospective evaluation.

Concepts Keywords
atherosclerotic cardiovascular disease
neuropsychiatric disorders
PCSK9 inhibitors
real‐world evidence
“””
// Werkzeug Debugger
EVALEX = false,
EVALEX_TRUSTED = false,
in __call__
line 1536,
NotImplementedError

Semantics

Type Source Name
drug DRUGBANK Alirocumab
drug DRUGBANK Evolocumab
disease MESH myocardial infarction
disease MESH heart failure
disease MESH ischaemic stroke
disease MESH death
disease MESH neurodegenerative disease
disease MESH dementia
disease MESH Parkinson’s disease
disease MESH psychiatric disorders
disease MESH psychosis
disease MESH bipolar disorder
disease MESH anxiety

Original Article

(Visited 49 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *